Next Article in Journal
Biology of Human Cutaneous Melanoma
Next Article in Special Issue
Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells
Previous Article in Journal
What Is Inflammatory Breast Cancer? Revisiting the Case Definition
Previous Article in Special Issue
Number of Axillary Lymph Node Metastases Determined by Preoperative Ultrasound is Related to Prognosis in Patients with Breast Cancer
Article

Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor

1
Stiftung Tumorbank Basel, Basel, Switzerland
2
Molecular Tumor Biology, Department of Research, Universitätsspital, Basel, Switzerland
3
Molecular Pathology, Institut für Pathologie, Universitätsspital, Basel, Switzerland
*
Author to whom correspondence should be addressed.
Cancers 2010, 2(1), 153-164; https://doi.org/10.3390/cancers2010153
Received: 25 January 2010 / Revised: 23 February 2010 / Accepted: 5 March 2010 / Published: 12 March 2010
(This article belongs to the Special Issue Breast Cancer)
The SH2 domain-containing adaptor protein ShcA is a proto-oncogene involved in growth factor receptor signaling. The role of phosphorylated ShcA is to link receptor tyrosine kinases with the SH2-containing adaptor protein Grb2, thus facilitating signal transduction from receptor tyrosine kinases to Ras, leading to MAPK activation. The present study was designed to investigate the prognostic significance of phosphorylated ShcA in primary breast cancer and its association in the interactions between the ER and ErbB2 pathways. Using a two-site chemiluminescence-linked immunosorbent assay, we detected the quantitative expression levels of total tyrosine- and threonine-phosphorylated ShcA in cytosol fractions obtained from fresh frozen tissue samples of 153 selected primary breast cancer patients. ShcA phosphorylation was not associated with nodal status, estrogen receptor (ER) status or grading. High levels of both tyrosine (pYShcA) and serine (pSShcA) phosphorylated ShcA correlated with good prognosis (p < 0.01), with respect to both disease-free (DFS) and overall survival (OS). In addition, pShcA levels were found to correlate with threonine-phosphorylated ErbB2 and inversely with phosphorylated Akt (pAkt), as well as ErbB2 and ER expression levels. Our findings demonstrate that ShcA activation in primary breast cancer patients correlates with low levels of ER, and is associated with good prognosis. View Full-Text
Keywords: ShcA; immunoassay; kinase; biomarker; estrogen receptor; phosphorylation; breast cancer ShcA; immunoassay; kinase; biomarker; estrogen receptor; phosphorylation; breast cancer
Show Figures

Figure 1

MDPI and ACS Style

Cicenas, J.; Küng, W.; Eppenberger, U.; Eppenberger-Castori, S. Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor. Cancers 2010, 2, 153-164. https://doi.org/10.3390/cancers2010153

AMA Style

Cicenas J, Küng W, Eppenberger U, Eppenberger-Castori S. Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor. Cancers. 2010; 2(1):153-164. https://doi.org/10.3390/cancers2010153

Chicago/Turabian Style

Cicenas, Jonas, Willy Küng, Urs Eppenberger, and Serenella Eppenberger-Castori. 2010. "Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor" Cancers 2, no. 1: 153-164. https://doi.org/10.3390/cancers2010153

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop